Objective: Soft tissue sarcomas (STSs) are rare malignancies deriving from mesenchyme. In this study, we reported the epidemiology of STS in China using population-based cancer registry data.
Introduction
Sarcomas, consisted of soft tissue sarcomas (STSs) and bone sarcomas, are a heterogeneous group of mesenchymal malignancies that can develop at any age, comprising approximately 1% of all adult malignancies and 15% of pediatric malignancies 1 . Compared with other common cancer types, STSs can develop at almost any anatomical sites 2 , and are more prone to occur at childhood 3 . Although the etiology of STSs is still unclear, known risk factors include inherited syndromes, chemical and radiation exposures, viral infections and genetic mutations 4, 5 .
Due to their rarity, STSs are always outnumbered by carcinomas in many primary sites, therefore not reported in most researches categorizing cancers with the International Classification of Diseases 6 . In United States, it is estimated that 13,040 new cases and 5,150 deaths were caused by STSs in 2018, representing 0.75% of overall cancer incidence and 0.84% of overall cancer mortality 7 . In Europe, nearly 23,600 new STS cases rose annually and the crude incidence rate was 4.7 per 100,000 6 . In UK alone 3,300 new cases were diagnosed each year, with about 90 cases in children under 15 years oldd 4 . So far, most national and subnational epidemiological researches on the burden of STSs were carried out in developed countries 3, [8] [9] [10] [11] [12] [13] [14] [15] .
Of all histological subtypes of STSs, gastrointestinal stromal tumor (GIST) was categorized as STS instead of digestive system cancer for the first time in the 2013 World Health Organization (WHO) Classification 5, 16 . Compared with other common cancer types in gastrointestinal tract, GIST starts in different types of cells and needs different types of treatment. Therefore, GIST was either treated as an entity equal to STSs and bone sarcomas 6, 17 , or reported separately from other STS subtypes [18] [19] [20] in some researches. The crude incidence rate of GIST was 1.1-1.4 per 100,000 according to French and Spanish researches 20, 21 . Stomach is the most common site for GIST 21 while there are some extremely rare tumors that arise outside the gastrointestinal tract but show the features of GIST. These tumors were therefore named extra-GIST 22 . Similar to the condition of overall STSs, few researches on the epidemiology of GIST and extra-GIST were carried out in developing countries.
With world's largest population, 23.7% of the global new cancer cases were estimated to occur in China in 2018 23 . However, little is known about the incidence of STS in this country. In order to have a comprehensive understanding on the cancer burden of STS in China, in this study we described the distribution of histological subtypes and primary sites of STS using updated data from 339 population-based cancer registries. Estimation of the incidence of STS in the whole Chinese population was made as well and was reported for GIST and STSs other than GIST (non-GIST STSs) separately. We also described the distribution of GIST and explored the proportion of extra-GIST.
Materials and methods

Cancer registry data source
By 30th August 2017, 449 cancer registries from 31 provinces in China submitted cancer registry data for 2014 to National Central Cancer Registry of China (NCCRC). Local population data were provided along with the cancer data. After quality control based on the criteria of Chinese Guideline for Cancer Registration, data from 339 registries met the criteria and were finally included in this analysis. Among them, 129 were located in urban areas (covering a population of 144,061,915) and 210 were in rural areas (covering a population of 144,181,432). The overall population covered by these 339 cancer registries was 288,243,347 (146,203,891 men and 142,039,456 women), accounting for 21.07% of the national population that year.
All cancer cases were coded according to the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Of all STS cases, the proportion of morphology verified cases (MV%) was 84.97%. More information on the national cancer registry program and data quality control procedure could be found elsewhere 24, 25 .
Data extraction, classification and statistical analysis
STS cases in the 339 registries were retrieved and categorized into different histological groups according to their ICD-O-3 morphological codes as shown in Table 1 based on a previous study 12 . The primary site of a case was defined by the ICD-O-3 topographical code. Cases with topographical codes being C40-C41 were deleted to exclude sarcomas in bones, joints and articular cartilages.
Crude incidence rates were calculated by area (urban/rural), sex (male/female) and age group (0, 1-4, 5 to 80 by 5 years, 85+) based on the retrieved cases. To estimate the number of new STS cases in the whole country, incidence rates stratified by area, sex and age group were multiplied by corresponding nationwide population in each stratum. National population data were obtained from Nation Bureau of Statistics. Chinese population in 2000 and World Segi's population were used for age-standardization.
The estimated nationwide incidence was reported for overall STSs, GIST, and non-GIST STSs separately. The distribution of histological subtypes was reported by sex and age group (0-19, 20-64, and over 65 years old) in order to reveal the sex and age predilection. Primary sites of all STS cases were classified into 14 groups and reported by sex.
Results
Incidence of soft tissue sarcoma
Approximately 39,900 new STS cases (19, 200 men and 20,700 women) occurred nationwide China in 2014, as shown in Table 2 . The crude incidence rate was 2.91/100,000 (2.72/100,000 in men and 3.11/100,000 in women), while the age-standardized rate by Chinese population (ASRcn) and world population (ASRwld) were 2.21 and 2.13 per 100,000, respectively.
There were 5,700 GIST cases (3,200 men and 2,500 women) nationwide in 2014, accounting for about 14.3% of the overall STSs. The crude incidence rate was 0.42/100,000 (0.45/100,000 in men and 0.38/100,000 in women). On the other hand, approximately 34,200 non-GIST cases (16,000 men and 18,200 women) were diagnosed, accounting for about 85.7% of the overall STSs. The crude incidence rate was 2.50/100,000 (2.27/100,000 in men and 2.73/100,000 in women). The incidence of overall STSs and non-GIST STSs were higher in women than in men in urban and rural areas, whereas the incidence of GIST was higher in men than in women in both areas.
As shown in Figure 1 , the age-specific incidence rates of overall STSs and non-GIST STSs were the lowest in children aged 5 to 9 years, increased dramatically after 35 years old and peaked at 75-79 years old in women and 80-84 years old in men for overall STSs, and 80-84 years old in both sexes for non-GIST STSs. As for GIST, the age-specific incidence rate was unstable due to the scarcity in individuals under 25 years old. The rate increased dramatically after 45 years old and peaked at 75-79 years old in women and 70-74 years old in men.
Distribution of histological subtypes
As shown in Table 3 , altogether 8,475 new STS cases (4,033 men and 4,442 women) were reported from the 339 cancer registries. The most common histological subtype was GIST (14.38%), followed by nerve sheath tumor and malignant peripheral nerve sheath tumor (MPNST) (12.48%), leiomyosarcoma (5.97%), liposarcoma (5.75%), and fibrosarcoma (5.73%).
Overall male/female ratio was 0.9, indicating a female predilection. Highest ratios were found in malignant myoepithelioma, clear cell sarcoma, malignant fibrous histiocytoma and primitive neuroectodermal tumor NOS, whereas lowest ratios were found in endometrial stromal sarcoma, granular cell tumors and alveolar soft part sarcoma, leiomyosarcoma, carcinosarcoma NOS, and myxosarcoma. Other specified soft tissue sarcoma
Carcinosarcoma, NOS M8980
Synovial sarcoma M9040-9043
Mixed tumor, malignant NOS M8940
Primitive neuroectodermal tumor, NOS M9364 and M9473
Granular cell tumors and alveolar soft part sarcoma M9580-9581
Paragangliomas and glomus tumors M8680-8711
Malignant mesenchymoma M8990
Malignant myoepithelioma M8982
Clear cell sarcoma M9044
Kaposi sarcoma M9140
Rhabdoid tumor M8963
Extraskeletal osteosarcoma and chondrosarcoma M9180-9243
Myxosarcoma M8840
Malignant giant cell tumors M9251 NOS: not otherwise specified
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Children and adolescents under 20 years old accounted for 3.12% of all STS cases, while adults aged 20-64 years and over 65 years accounted for 64.64% and 32.24%, respectively. In major histological subtypes, children and adolescents represented 44.63% of all rhabdomyosarcoma cases, whereas endometrial stromal sarcoma (84.13%) and nerve sheath tumor and MPNST (80.72%) occurred mainly in adults aged 20 to 64 years, and proportions of malignant fibrous histiocytoma (47.93%) and GIST (43.07%) were relatively high in elders above 65 years old.
Distribution of primary sites
As shown in Table 4 , more than 22% of STSs were located in the connective, subcutaneous and other soft tissues, of which 574 were in lower limb and hip (lower extremities), 234 were in upper limb and shoulder (upper extremities). About one-fifth of STSs occurred in digestive organs, of which 952 were in stomach, 294 were in small intestine, and 153 were in liver. Retroperitoneum and peritoneum and eye, brain and other parts of the central nervous system both accounted for nearly 14% of all STSs. As shown in Table 5 , of all GIST cases, 98.6% arose in digestive organs. Stomach was the most common site (67.51%), followed by small intestine (20.92%), other digestive organs (4.59%) and rectum (3.12%). Extra-GIST was found in retroperitoneum and peritoneum, bronchus and lung, soft tissues, thyroid gland, and other unknown sites, representing 1.4% of all GIST cases.
Discussion
In this study, using population-based cancer registry data, we found that nearly 39,900 new STS cases (5,700 GIST and 34,200 non-GIST) were diagnosed nationwide in China in 2014, representing 1.05% (0.90% in male, 1.23% in female) of all cancer incidence 24 
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in United States 7 . Crude incidence rates of STSs and GIST were 2.91 and 0.42 per 100,000 respectively, lower than the corresponding rates in western countries (4.7 and 0.78 per 100,000) 6, 19 . Incidence of STS in China generally increased with age. The rate in Austria showed similar trend but peaked and dropped at younger ages 14 . Unlike carcinomas, STSs comprise a large proportion of pediatric malignancies and are an important cause of death in adolescents and young adults 3, 4 . In our study, 3.1% of all STSs occurred in individuals aged 0 to 19 years, whereas in United States and Japan, corresponding proportions were 5.6% and 6.7%, respectively 3, 12 . Rhabdomyosarcoma was the only entity with a median age < 20 years in United States. It was also the most common subtype in people under 20 years old in these three studies. Unlike most carcinomas, to which men are prone to develop, contradictions remained as for the major gender of STS patients. In Europe, there were more female patients 6, 14 , while in Korea and Taiwan China, results showed the opposite 13, 26 . Similar to these Asian results, men outnumbered women in most primary sites and histological subtypes in our study. However, there were more female patients due to the numerous cases in breast and female genital organs, and subtypes like leiomyosarcoma, which occurs mainly in genital organs, bladder and uterus.
GIST was the most common histological subtype in Chinese population, as was found in Europe 15 . In France, 16.7% of the identified sarcoma cases were GIST. French distribution of GIST was similar to our study, with 61% and 27% arose in stomach and small intestine, respectively. The proportion of extra-GIST nevertheless was greater because 5% of GIST arose in peritoneum. This extravagant percentage can be partly explained by the small sample size 21 . In contrast to our and American results 19 , GIST showed a female predilection in France. In United States, there were relatively less GIST in stomach (55.3%) and more in small intestine (28.7%), while the proportion of extra-GIST was 3.0%, also larger than our result 19 . Kaposi sarcoma, accounting for less than 0.6% of all STSs, was only a minor subtype in China and even less common (0.2%) in Japan 12 , whereas it had very high incidence in African countries 27 . Kaposi sarcoma is also the most common subtype (31.7%) in United States 3 . This could be explained by the relatively low prevalence of HIV in East Asia because Kaposi sarcoma is strongly related with immune suppression 28 .
Other than Kaposi sarcoma, common subtypes in United States were fibrohistiocytic tumors (30.4%) and leiomyosarcoma (27.4%) 3 . Even after the inclusion of GIST into the leiomyosarcoma category, corresponding proportions in our study, which were 5.12% and 20.35% respectively, were still smaller than these results. In Japan, leiomyosarcoma (28.1%) was the most prevalent subtype, followed by liposarcoma (9.6%), and malignant fibrous histiocytoma (9.0%) 12 . In contrast, nerve sheath tumor and MPNST is far more prevalent in China, representing more than 12% of all STSs in our study, compared with 3.5% in Japan and 4.6% in United States.
In terms of primary sites, according to American Cancer Society, STSs can develop in soft tissues, internal organs as well as retroperitoneum 29 . However, the WHO classification did not include internal organs as primary sites for STSs and listed only the extremities, trunk wall, and retroperitoneum 5 . Therefore, STSs were recognized as an entity with a variety of primary sites in some studies [10] [11] [12] 14 , while in others, STSs were more confined and sarcomas in internal organs were categorized as visceral sarcoma separately 8, 15 .
In this study, we used the classification of American Cancer Society, and found that connective, subcutaneous and other soft tissues was the most common site. Delving into more specific topographic categories, lower extremity was the most common subsite, and the number of cases in lower extremity was 2-3 times of that in upper extremity. Results in Korea 13 , Japan 12, 30 and Europe 15 further proved ours. Digestive organs, which was recognized as visceral sarcomas in some studies, were the second most common site for STSs, of which the majority was GIST. We found 17 extremely rare extra-GIST cases based on this large population-based study. This will provide valuable epidemiological evidence for further researches.
STSs have more than 70 histological subtypes 15 . Together with the various primary sites, they make up a large number of combinations that vary tremendously in terms of survival 30 , and would worsen along with ageing 3 . This, together with its scarcity, emphasize that more attention should be paid to this less noticed disease and its patients. Some limitations of this study should be noticed. First, probable methodology bias remains. We retrieved data based on ICD-O-3 morphological codes in this study because STSs can arise in almost every part in the human body, making topographical codes less useful than in the analysis of carcinomas. Nevertheless, according to a European study, nearly 42% of the first histological diagnoses of STSs were inaccurate. This heterogeneity and discrepancy can lead to misreport on subtype incidence 4, 32 and consequently bias the results on the epidemiology of STSs. Second, proportion of sarcoma NOS was too high compared with Japanese results 12 , and MV% was lower than that in Europe 6 , indicating a necessity to strengthen the pathological diagnosis especially in rural China.
Conclusions
This study is the first in China mainland to report the nationwide incidence of STS as well as the distribution of histological subtypes and primary sites. As a group of rare malignancies in China, STSs are more common in children than carcinomas. With numerous histological subtypes and primary sites, tremendous variations remain in STSs, which impose an arduous challenge to both medical researchers and doctors and emphasize more attention.
